Cargando…
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
BACKGROUND: Human sarcomas with a poor response to vascular endothelial growth factor-A (VEGF-A) inhibition and radiation therapy (RT) have upregulation of hypoxia-inducible factor 1α (HIF-1α) and HIF-1α target genes. This study examines the addition of the hypoxia-activated chemotherapy TH-302 to V...
Autores principales: | Yoon, C, Lee, H-J, Park, D J, Lee, Y-J, Tap, W D, Eisinger-Mathason, T S K, Hart, C P, Choy, E, Simon, M C, Yoon, S S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647529/ https://www.ncbi.nlm.nih.gov/pubmed/26010414 http://dx.doi.org/10.1038/bjc.2015.186 |
Ejemplares similares
-
Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma
por: Shannon, A M, et al.
Publicado: (2005) -
A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
por: Mellor, H R, et al.
Publicado: (2005) -
The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008) -
VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008) -
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
por: Chatelut, E, et al.
Publicado: (2012)